JANX

Over the past six months, Janux Therapeutics' stock has been influenced by several key events. Positive interim clinical data for JANX007 and a collaboration agreement with Bristol Myers Squibb positively impacted investor sentiment. Financial results for Q4 2025 and Q1 2026 showed collaboration revenue and a strong cash position, while the nomination of a development candidate under the Bristol Myers Squibb collaboration triggered a milestone payment. The first patient was dosed in a Phase 1 study of JANX014, marking pipeline progress. The discontinuation of clinical development for JANX008 was announced, reflecting resource prioritization.